Mylan's Coury on Teva: deal 'without logic'
This article was originally published in Scrip
"Such a combination is without sound industrial logic or cultural fit." So said Mylan's executive chairman Robert Coury in response to speculation over a potential bid for the company by rival Teva Pharmaceutical Industries. He said Mylan had studied the potential combination of the two companies "for some time", and added that it was unlikely it would obtain antitrust clearance given the "significant overlap" in their businesses.